| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-08-19 |
| タイトル |
|
|
タイトル |
Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Jubashi, Amane
Nakayama, Izuma
Sakamoto, Naoya
Takei, Shogo
Matsubara, Yuki
Miyashita, Yu
Sato, Seiya
Ushiyama, Shinpei
Kobayashi, Akinori
Okazaki, Ukyo
Okemoto, Dai
Yamamoto, Kazumasa
Mishima, Saori
Kotani, Daisuke
Kawazoe, Akihito
Hashimoto, Tadayoshi
Nakamura, Yoshiaki
Kuboki, Yasutoshi
Bando, Hideaki
Kojima, Takashi
Yoshino, Takayuki
Kuwata, Takeshi
Sato, Kazuma
Fujita, Takeo
Yoshida, Mitsumasa
Yura, Masahiro
Kinoshita, Takahiro
Shitara, Kohei
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Purpose: Perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is a standard treatment for locally advanced gastric/gastroesophageal junction cancer (GC/GEJC). The impact of biomarker status on the efficacy of perioperative FLOT remains unclear. This study evaluated the association between clinicopathological features, including biomarker status, and the efficacy of perioperative FLOT in patients with resectable GC/GEJC. Patients and Methods: A retrospective observational study was conducted by reviewing medical records of patients treated with perioperative FLOT between February 2020 and March 2024. Eligible patients had histologically confirmed adenocarcinoma, resectable disease at stages cT2-4a and/or N0-3, M0, and underwent biomarker testing. Results: Among 116 eligible patients, human epidermal growth factor receptor 2 (HER2) positivity was observed in 7.8%, whereas PD-L1 combined positive score (CPS) of ≥1, ≥5, and ≥10 was detected in 90.5%, 44.0%, and 15.5% of patients, respectively. Claudin-18 isoform 2 (CLDN18.2) positivity (2+/3+ in ≥75% of tumor cells) was observed in 30.2% of patients. Major pathological response (MPR) and pathological complete response (pCR) rates were 22.4% (95% CI, 15.3 to 31.0) and 8.6% (95% CI, 4.2 to 15.3), respectively. Diffuse-type histology was a negative indicator for pathological response. CLDN18.2 expression decreased significantly after preoperative FLOT, with the median H-score declining from 285.0 to 187.5 (P < .001) in patients with CLDN18.2 positivity at initiation. Maintained CLDN18.2 positivity was more frequently observed in patients without MPR compared with those with MPR (53.8% v 12.5%, P = .05). Conclusion: HER2, PD-L1, and CLDN18.2 statuses were not linked to pathological response to FLOT in resectable GC/GEJC. CLDN18.2 expression significantly decreased after preoperative FLOT but remained higher in patients without MPR, suggesting that CLDN18.2-targeted therapy may warrant investigation in the perioperative setting. |
|
言語 |
en |
| 書誌情報 |
en : JCO Precision Oncology
巻 9,
p. art. no. e2400925,
発行日 2025-08-01
|
| 出版者 |
|
|
出版者 |
American Society of Clinical Oncology |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2473-4284 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1200/PO-24-00925 |
| 権利 |
|
|
権利情報 |
© 2025 by American Society of Clinical Oncology. Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/ |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
JCO Precision Oncology, 9, art. no. e2400925; 2025 |
|
言語 |
en |
JCOP09_e2400925.pdf (1.3 MB)
